Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer

Helmut Oettle; Stefan Post; P. Neuhaus; Klaus Gellert; Jan M. Langrehr; Karsten Ridwelski; H Schramm; J. Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; E. Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf O. Bechstein; Marco Niedergethmann; Ingo Schmidt‐Wolf; L. Roll; Bernd Doerken; Hanno Riess

doi:10.1001/jama.297.3.267

JOURNAL ARTICLE

Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer

Helmut Oettle Stefan Post P. Neuhaus Klaus Gellert Jan M. Langrehr Karsten Ridwelski H Schramm J. Fahlke Carl Zuelke Christof Burkart Klaus Gutberlet E. Kettner Harald Schmalenberg Karin Weigang-Koehler Wolf O. Bechstein Marco Niedergethmann Ingo Schmidt‐Wolf L. Roll Bernd Doerken Hanno Riess

Year: 2007 Journal: JAMA Vol: 297 (3)Pages: 267-267 Publisher: American Medical Association

DOI: 10.1001/jama.297.3.267

Get Full-Text PDF Get Analytical Report

Abstract

isrctn.org Identifier: ISRCTN34802808.

Keywords:

Medicine Gemcitabine Pancreatic cancer Clinical endpoint Internal medicine Chemotherapy Surgery Oncology Cancer Randomized controlled trial

Metrics

2364

Cited By

71.80

FWCI (Field Weighted Citation Impact)

Refs

1.00

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Pancreatic and Hepatic Oncology Research

Health Sciences → Medicine → Oncology

Cancer Genomics and Diagnostics

Life Sciences → Biochemistry, Genetics and Molecular Biology → Cancer Research

Gastric Cancer Management and Outcomes

Health Sciences → Medicine → Pulmonary and Respiratory Medicine

Related Documents

JOURNAL ARTICLE